Potential Clinical Value of 5-Hydroxytryptamine Receptor 3C as a Prognostic Biomarker for Lung Cancer

Table 1

Correlation between HTR3C expression levels and various clinicopathological characteristics in lung cancer.

Variables	Item	Patient no. (%)	HTR3C				value
			Low (≤92.62)		High (>92.62)
			No.	%	No.	%
		128 (100.0)	58	45.3	70	54.7
Age (y)	≤70	98 (76.6)	41	70.7	57	81.4	0.153^a
	>70	30 (23.4)	17	29.3	13	18.6
Sex	Female	46 (35.9)	18	31.0	28	40.0	0.293^a
	Male	82 (64.1)	40	69.0	42	60.0
Grade	I	29 (22.7)	10	17.2	19	27.1	0.183^a
	II/III	99 (77.3)	48	82.8	51	72.9
T status	T1/T2	107 (83.6)	45	77.6	62	88.6	0.095^a
	T3/T4	21 (16.4)	13	22.4	8	11.4
N status	Negative (N0)	68 (53.1)	37	63.8	31	44.3	0.028^a
	Positive (N1/N2/N3)	60 (46.9)	21	36.2	39	55.7
M status	Negative	110 (85.9)	54	90.2	56	76.6	0.042^b
	Positive	18 (14.1)	4	9.8	14	23.4
Histology	Adenocarcinoma	97 (78.2)	43	75.4	54	80.6	0.488^a
	Squamous cell carcinoma	27 (21.8)	14	24.6	13	19.4
Performance	0	85 (66.4)	40	69.0	45	64.3	0.577^a
	1	43 (33.6)	18	31.0	25	35.7
Smoking status	Never	76 (59.4)	34	58.6	42	60.0	0.472^a
	Former	22 (17.2)	8	13.8	14	20.0
	Current	30 (23.4)	16	27.6	14	20.0
Recurrence	No	58 (45.3)	37	63.8	21	30.0	<0.001^a
	Yes	70 (54.7)	21	36.2	49	70.0
Cancer death	No	93 (72.7)	53	91.4	40	57.1	<0.001^b
	Yes	35 (27.3)	5	8.6	30	42.9

^a value was calculated by the chi-square test. ^b value was calculated by Fisher’s exact test.